Thymosin Beta-4

TB-4's primary structural function is sequestering monomeric G-actin in a 1:1 complex, maintaining a large pool of available actin monomers for rapid filament assembly. When cells need to rapidly remodel their cytoskeleton (during migration, division, or wound closure), this TB-4-bound actin pool provides immediate substrate. In wound healing, this function directly accelerates keratinocyte and fibroblast migration into wound beds. The LKKTETQ sequence (which constitutes TB-500) contains the actin-binding motif and accounts for this primary mechanism. TB-500 as a synthetic fragment captures most of this activity at a smaller molecular weight, explaining its similar healing efficacy.

TB-4 is a potent stimulator of angiogenesis through multiple mechanisms: upregulation of VEGF, promotion of endothelial cell migration and tube formation, and activation of ILK (integrin-linked kinase) signaling that drives endothelial survival and proliferation. In ischemic tissue models, TB-4 injection promotes collateral vessel formation and restores blood flow. The cardiac repair studies from the Bhattacharya lab at NYU Medical Center showed that TB-4 pre-treatment before experimental MI and post-MI treatment both significantly improved cardiac function by promoting epicardial-derived progenitor cell differentiation and coronary vasculogenesis.

TB-4 reduces TGF-beta-driven fibrotic gene expression (collagen I, fibronectin, alpha-SMA) in myofibroblasts, making it relevant to organ fibrosis in the heart, liver, kidney, and lung. It also promotes macrophage polarization toward the M2 (anti-inflammatory, pro-resolution) phenotype and reduces neutrophil migration into injury sites. These anti-fibrotic and anti-inflammatory properties complement the angiogenic and cytoskeletal effects to enable complete wound resolution rather than scar formation.

RegeneRx completed Phase II trials showing topical TB-4 (RGN-259 eye drops) significantly improved dry eye disease endpoints (corneal staining, visual clarity) vs placebo. A Phase III trial in neurotrophic keratopathy (damaged corneal nerves) was completed with positive results. For skin wound healing, Phase II data showed faster wound closure and reduced scar formation in acute and chronic wounds. The ocular program is the most clinically advanced application.

The RESET trial (Phase II, 93 patients) evaluated IV TB-4 after acute MI. While the primary endpoint (wall motion score index) did not reach significance, secondary endpoints (regional ejection fraction, exercise capacity) showed positive trends. The preclinical data from mouse and porcine MI models is very strong, TB-4 administered after experimental MI consistently improves ejection fraction by 10-15% versus placebo. The translational gap may reflect dosing, timing, or patient selection issues in the human trial.

The LKKTETQ fragment (TB-500) captures the actin-binding and cell migration-promoting activities of full-length TB-4 in a smaller, more practical molecule. Full-length TB-4 has additional activities including: PINCH (particularly interesting new cysteine-histidine rich protein) interaction supporting cell survival, direct binding to the p53 family member p63, and transcriptional activation roles. Whether these additional activities confer meaningful clinical advantages over TB-500 has not been definitively established in comparative studies. TB-4 is the better-studied molecule in formal clinical trials; TB-500 is more widely used in the research community.